In this presentation from the “CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer – Advancing Nursing Care to Improve Patient Outcomes” symposium held during the 2016 Annual Meeting of the Oncology Nursing Society, Meg Trewhitt Discusses how to council ER+ metastatic breast cancer patients on efficacy expectations for CDK 4/6 inhibitors.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content